RxDoctor Payments DataLook up a doctor →

Monica Benavidez, DO

Psychiatry · Phoenix, AZNPI 1710182225

Payments from drug & device makers

$434,729in general payments, 2019–2025

Across 1,287 payments — averaging $337.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$240K
  • E.r. Squibb & Sons, L.L.C.$95K
  • Alkermes, Inc.$92K
  • Johnson & Johnson$2K
  • Neurocrine Biosciences, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • plus $3K from 6 others

What the payments were for

  • Consulting fees$16,5944%
  • Speaking & faculty fees$318,04473%
  • Travel & lodging$72,23917%
  • Food & beverage$27,5936%
  • Education$2590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$434,729 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.

See all psychiatry providers in Arizona

Medicare billing

Part B allowed, 2024
$22,048
Medicare patients
25
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UzedyRisperidone83$526,539
AristadaAripiprazole Lauroxil101$345,214
LybalviOlanzapine/Samidorphan Malate301$287,160
IngrezzaValbenazine Tosylate14$104,780
Invega SustennaPaliperidone Palmitate27$91,593
CaplytaLumateperone Tosylate13$20,498
Clozapine266$11,067
Divalproex Sodium ErDivalproex Sodium201$5,493
Haloperidol Decanoate108$5,169
Lurasidone Hcl58$4,032
Trazodone Hcl279$2,585
Benztropine Mesylate207$2,555
Fluphenazine Hcl20$2,416
Quetiapine Fumarate120$1,906
Bupropion XlBupropion Hcl116$1,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada, Lybalvi$91,701$632,374402 claims
Teva Pharmaceuticals USA, Inc.Uzedy$239,775$526,53983 claims
Neurocrine Biosciences, Inc.Ingrezza$1,523$104,78014 claims
Johnson & JohnsonInvega Sustenna$2,185$91,59327 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,255$20,49813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.

Other psychiatry in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →